Technical Articles

combination therapy

重组人cd40 fc蛋白：CD40 激动方向为什么在免疫肿瘤学里一直被寄予期待？

CD40 Agonism in Immuno-Oncology: Why Expectations Stay High

2026-10-16

This article reviews CD40 agonism in immuno-oncology research: licensing dendritic cells, reversing the cold tumor phenotype, the safety trade-offs of systemic agonism and what standardized CD40 reagents contribute to preclinical workflows.

View details

Immunity/Inflamma
CD40 agonist
immuno-oncology
dendritic cell licensing
cold tumor
combination therapy
UA010194

重组小鼠m-csf蛋白：从集落刺激因子到 CSF1R 策略，它为什么成了免疫微环境的入口？

M-CSF in Drug Development: The CSF1R Gateway to the Immune Microenvironment

2026-10-14

CSF1R inhibitors opened macrophage-focused immunotherapy strategies. This article reviews CSF1R-directed approaches, tumor-associated macrophages and how recombinant mouse M-CSF supports translational research.

View details

Immunity/Inflamma
M-CSF
CSF1R
TAM
immune microenvironment
osteoclast
combination therapy
translational research
UA040128

Clinical Setbacks of IGF1R Antibodies: From Figitumumab Monotherapy to a Combination-Treatment Paradigm Shift

2026-10-08

After figitumumab monotherapy failed, the IGF1R antibody field shifted toward combination treatment and biomarker stratification. This article traces the paradigm shift in IGF1R translational research and its in vitro tool support.

View details

Cancer
IGF1R antibodies
figitumumab
ganitumab
combination therapy
biomarkers
tumor targeting
UA016082
alpha2beta2

Total 3

Go to